Cite
MLA Citation
J. Hsu et al.. “XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile.” European journal of cancer, vol. 138, n.d., pp. S16–. http://access.bl.uk/ark:/81055/vdc_100120050549.0x000023